Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3515 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Asma El-Zailik und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vir Biotechnology, Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Vir Biotechnology, Inc., GSK, Vir Biotechnology.
Abstract (Originalsprache)
Sotrovimab is a recombinant human monoclonal antibody for the early treatment of mild‐to‐moderate COVID‐ 19. A phase I, open‐label, randomized, parallel‐group study was conducted to investigate the pharmacokinetics, relative bioavailability, safety, and tolerability of two concentrations of sotrovimab administered intramuscularly at different injection sites in healthy volunteers. The study consisted of three parts (A, B, and C) and the pharmacokinetic results from Part A are reported herein. In Part A, participants were randomized in a 2:2:1:1 ratio to a 500 mg dose of 62.5 mg/mL sotrovimab administered into dorsogluteal muscle, or 100 mg/mL sotrovimab administered into dorsogluteal, anterolateral thigh, or deltoid muscles. Formulation concentration did not impact exposure following dorsogluteal administration; the point estimates (90% confidence interval [CI]) of the geometric mean ratios (GMRs) of area under the curve (AUC) inf and maximum serum concentration ( C max ) for dorsogluteal administration of 100 mg/mL vs. 62.5 mg/mL intramuscular sotrovimab were 0.95 (0.86–1.05) and 1.14 (1.02–1.27), respectively. However, the administration of 100 mg/mL sotrovimab in thigh or deltoid resulted in increased exposure relative to gluteal injections; the point estimates (90% CI) of the GMRs for 100 mg/mL intramuscular sotrovimab administered into thigh or deltoid muscles vs. 100 mg/mL administered dorsogluteally were 1.63 (1.46–1.83) and 1.50 (1.34–1.67) for AUC inf , and 1.82 (1.60–2.08) and 1.49 (1.31–1.69) for C max , respectively. Notably, thigh and deltoid administration also resulted in lower variability in key pharmacokinetic parameters such as AUC, C max , apparent clearance and volume of distribution, and earlier achievement of C max , than dorsogluteal intramuscular administration of sotrovimab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vir Biotechnology, Inc., San Francisco, California, USA.
- GSK, Brentford, UK.
- GSK, Bengaluru, India.
- GSK, Stevenage, UK.
- GSK, Cambridge, Massachusetts, USA.
ORCID-Profile: Asma El-Zailik, Yasmin Sánchez-Pearson, Sergio Parra
Förderung
- Vir Biotechnology, Inc.
- GSK
- Vir Biotechnology
- GlaxoSmithKline Japan
Zitieren
APA
El-Zailik, A., Sager, J., Sánchez-Pearson, Y., Parra, S., Moore, J., Sarkar, P., Aylott, A., Wang, Q., Aldinger, M., Garner, C., Mogalian, E., Skingsley, A., Peppercorn, A., & Reyes, M. (2025). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3515
Vancouver
El-Zailik A, Sager J, Sánchez-Pearson Y, Parra S, Moore J, Sarkar P, et al. Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3515
BibTeX
@article{ElZailik2025,
author = {El-Zailik, Asma and Sager, Jennifer and Sánchez-Pearson, Yasmin and Parra, Sergio and Moore, Jennifer and Sarkar, Prosenjit and Aylott, Alicia and Wang, Qianwen and Aldinger, Melissa and Garner, Chad and Mogalian, Erik and Skingsley, Andrew and Peppercorn, Amanda and Reyes, Maribel},
title = {Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3515}
}
EUVIMED